StreetAlpha.app
Home › Stocks › KRSA

Korsana Biosciences, Inc. (KRSA)

Healthcare
$32.50
▼ −0.55%
LAST CLOSE · NOV 17

Korsana Biosciences is developing CYC-126, a personalized anesthesia treatment for depression that has not responded to standard antidepressants. It last closed at $32.50 on Nov 17, down 0.55% on the day. The average 12-month price target from 5 analysts is $51.20 (+57.5% from the last close), with a high of $70.00 and a low of $43.00. Analyst consensus is Strong Buy, based on the latest ratings from 5 firms (5 buy, 0 hold, 0 sell). In the past 30 days there were 1 dark pool print totaling $789K, the largest $789K.

AI Auto Pilots
Is KRSA in one of our four AI portfolios? Sign in free to see

Key Stats

Last 12 months
Results
Net income
−$58.9M
Valuation
Market cap
$1.5B
45.5M shares
P/E
–
Dividend yield
None
No dividend in 12 months
Balance sheet
Cash & equivalents
$456.2M
At Sep 30
Shareholder equity
$391.6M
Shares outstanding
45.5M
At Nov 2
Fiscal year endsDecember
ExchangeNasdaq
Financials history
FY2021: $3.9M$3.9MFY2021FY2022: $297K$297KFY2022FY2023: $0$0FY2023FY2024: $2.0M$2.0MFY2024FY2025: $2.1M$2.1MFY2025

From KRSA's SEC filings, latest 10-Q for the period ending Sep 30, 2026 (filed Nov 5). Last 12 months adds up the four latest quarters.

Last report
Nov 5
2026 · next date not on the calendar yet
Consensus EPS forecast
—
 
Year-ago EPS
—
Not on file
Options-implied move
—
 
Analyst consensus
Strong Buy
Based on 5 analyst ratings (90 days)
Loading…

Analyst Ratings & Price Targets

Analyst Ratings →
Consensus · 90 days
Strong Buy
5firms
5 Buy0 Hold0 Sell
Each firm's latest rating on KRSA in the past 90 days
Average 12-month target
$51.20
▲ 57.5% upside

Based on 5 analysts who set a price target on KRSA in the past 90 days. The average target is $51.20, with a high of $70.00 and a low of $43.00, compared with the last close of $32.50.

Low $43.00Avg $51.20High $70.00
Blue marker: last close $32.50
Highest target$70.00
Average target$51.20
Lowest target$43.00
Latest rating changes
Wells FargoInitiated
Nov 13Buy$44
WedbushInitiated
Oct 5Buy$44
GuggenheimInitiated
Sep 28Buy$70
StifelInitiated
Sep 14Buy$43
UBSInitiated
Sep 11Buy$55
DateFirmActionRatingPrice target
Nov 13Wells FargoInitiatedBuy$44
Oct 5WedbushInitiatedBuy$44
Sep 28GuggenheimInitiatedBuy$70
Sep 14StifelInitiatedBuy$43
Sep 11UBSInitiatedBuy$55
Loading…

Technical Analysis

KRSA · as of the Nov 17 close · updated after every close
Uptrend

The stock is 3% above its 20 day and 2% above its 50 day average. It is 28% above its 200 day average, so the longer trend is still up. Momentum is strong (RSI 54). The nearest support is the Pivot at $32.09, and the nearest resistance the swing high (Nov 4) at $33.44.

Short trendBullish
Long trendBullish
MomentumStrong
StretchNormal
VolatilityNormal, 7.0%/day
Key levels
$59.3652 week high+82.6%
$33.50Pivot R1+3.1%
$33.44Swing high (Nov 4)+2.9%
$32.50Last close
$32.09Pivot−1.3%
$31.8250 day average−2.1%
$31.3720 day average−3.5%
$31.10Pivot S1−4.3%
$30.78Swing low (Oct 14)−5.3%
$29.03100 day average−10.7%
$23.25200 day average−28.5%
$7.1952 week low−77.9%
Indicators
RSI (14)54.42Middle of its rangeNeutral
MACD0.11Above its signal lineBullish
Stochastic64.0Middle of its rangeNeutral
ADX (14)13.0No clear trend
Williams %R-34.3Oversold below −80, overbought above −20Neutral
CCI (20)70.0Oversold below −100, overbought above 100Neutral
Rate of change+1.7%Change over 10 sessionsBullish
ATR (14)$2.26Typical daily range, 7.0% of price
MA 10Above
MA 20Above
MA 50Above
MA 100Above
MA 200Above
What happened before, for KRSA

What happened before

See how KRSA did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record.

November seasonalityHow KRSA usually does this month. See Seasonality

Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.

Seasonality

How KRSA has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2019.

Loading…

See the stocks that usually rise in November →

Whale Options Flow

90D

No whale options trades in KRSA in the last 90 days.

Loading…

See today’s whale options flow across the market →

Dark Pool

30D
Prints
1
Notional
$789K
Largest print
$789K
Loading…

KRSA Institutional Ownership

Full report →
Fund sentiment · Q3 2026
Bullish
Strongly bearishNeutralStrongly bullish
  • ▲43 buying vs 0 selling
  • ▲Held by funds +86.7 pts
  • ●Funds holding +44
  • ▲Superinvestors: 3 added, 0 cut
  • ●Put/call not meaningful
Q3 2026This quarterLast quarterChange
Funds holding44––
In funds' top 109––
Held by funds86.7%––
New / increased43 / 0––
Reduced / sold out0 / 0––
Put/call ratio–––
Top holders, biggest buyers and sellers, 8 quarters of charts and this season's filings so far.See KRSA institutional ownership →

From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.

AI Auto Pilots

Paper trading

StreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether KRSA is in one of them and how their past KRSA trades turned out.

KRSA in the AI portfolios
Loading…

Macro & Market News

All StreetAlpha news →

StreetAlpha hasn't covered KRSA in an article yet. Here's the latest on the wider market.

About Korsana Biosciences

Korsana Biosciences is a drug developer based in Waltham, Massachusetts, focused on serious neuropsychiatric disorders. Its lead program, CYC-126, is being developed as a treatment for depression that has not responded to at least two antidepressant treatments. The approach combines two widely used anesthetic agents, propofol and dexmedetomidine, with a delivery system that monitors brain activity so dosing can be tailored to each patient. It is designed for use in hospital settings under the care of anesthesiologists. The company is also working to license its older sGC stimulator assets to other firms.

Headquarters
Waltham, MA